|
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Radiopharmaceuticals targeting the enzyme prostate-specific membrane antigen (PSMA; synonyms: glutamate carboxypeptidase II, NAALADase; EC 3.4.17.21) have recently emerged as powerful agents for diagnosis and therapy (theranostics) of prostate carcinoma (PCa).
|
30011372 |
2018 |
|
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Moreover, in PSM group, three uniquely identified proteins (cyclin-dependent kinase 6, galectin-3-binding protein and L-lactate dehydrogenase C chain) were found, which show tight connection with prostate cancer and presence of all of them was previously linked to certain aspects of prostate cancer.
|
26503549 |
2015 |
|
Prostate carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Differential ultracentrifugation, cell surface biotinylation, Western blotting, and enzyme activity measurement were used to study the origin and localization of the PSMA/PSM' variants in prostatic (LNCaP; lymph-node carcinoma of the prostate) and non-prostatic (HEK293) cell lines.
|
19107881 |
2009 |
|
Prostate carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
PSM-E and PSMA mRNA were detected in PCa and LNCaP, not in PC-3; PSMA could be detected in some nonprostatic tumors whereas PSM-E not.
|
17929272 |
2007 |
|
Prostate carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
The ratio of PSMA to PSM' mRNA was higher in a small number of prostate cancer specimens compared to normal prostate cancer and benign prostatic hypertrophy (Su et al.Cancer Res 1995;55:1441).
|
12949815 |
2003 |
|
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
PSM' mRNA induced false-positive results, it is important for genetic diagnosis of prostate cancer to discriminate between PSM and PSM' using our primer sets with high specificity.
|
12373303 |
2002 |
|
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Gene therapy using the PSM promoter to drive prostate-specific expression of various cytokines and other factors is another exciting potential application deserving of attention, and refinement of serum PSM assays may greatly add to the present array of diagnostic modalities offered to patients with suspected prostate cancer.
|
9126242 |
1997 |
|
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
Moreover, in PSM group, three uniquely identified proteins (cyclin-dependent kinase 6, galectin-3-binding protein and L-lactate dehydrogenase C chain) were found, which show tight connection with prostate cancer and presence of all of them was previously linked to certain aspects of prostate cancer.
|
26503549 |
2015 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen.
|
17929272 |
2007 |
|
Malignant neoplasm of prostate
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
PSM-E and PSMA mRNA were detected in PCa and LNCaP, not in PC-3; PSMA could be detected in some nonprostatic tumors whereas PSM-E not.
|
17929272 |
2007 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The expression of PSM-D was similar in normal and primary prostate cancer but was 2-fold higher in lymph node (p < 0.005) and bone metastases (p < 0.05) compared to the primary tumors.
|
12949815 |
2003 |
|
Malignant neoplasm of prostate
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The ratio of PSMA to PSM' mRNA was higher in a small number of prostate cancer specimens compared to normal prostate cancer and benign prostatic hypertrophy (Su et al.Cancer Res 1995;55:1441).
|
12949815 |
2003 |
|
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
PSM' mRNA induced false-positive results, it is important for genetic diagnosis of prostate cancer to discriminate between PSM and PSM' using our primer sets with high specificity.
|
12373303 |
2002 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Surprisingly, we identified a tumor cell line that is resistant to the cell cycle inhibitory effects of PSM-RB.
|
10498874 |
1999 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Further research with PSM may help us to elucidate the complex process of prostatic neoplasia better.
|
9126242 |
1997 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
PSM has many properties that may be potentially useful as a molecular target in monoclonal antibody directed strategies of tumor imaging and therapy.
|
9215402 |
1997 |
|
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
Gene therapy using the PSM promoter to drive prostate-specific expression of various cytokines and other factors is another exciting potential application deserving of attention, and refinement of serum PSM assays may greatly add to the present array of diagnostic modalities offered to patients with suspected prostate cancer.
|
9126242 |
1997 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond.
|
30844704 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
HALNU seemed to present lower risk of PSM (0.02; 95% CI - 0.01, 0.05), and lower risk of recurrence (0.22; 95% CI 0.15, 0.30), metastasis (0.07; 95% CI 0.05, 0.10), and cancer-related death (0.03; 95% CI 0.01, 0.06).
|
31773242 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond.
|
30844704 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The presence of PSM suggests inadequate cancer clearance and the possible need for additional treatment.
|
26503549 |
2015 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
The presence of PSM suggests inadequate cancer clearance and the possible need for additional treatment.
|
26503549 |
2015 |
|
Retinoblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Surprisingly, sustained PSM-RB expression impeded the proliferation of SiHa cells, resulting in both cell cycle inhibition and cell death.
|
18506774 |
2009 |
|
Retinoblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, phosphorylation of the retinoblastoma tumor suppressor protein (RB) is still required for G1-S progression in androgen-independent cells, since the expression of constitutively active RB (PSM-RB) or p16ink4a caused cell cycle arrest and mimicked the effects of androgen withdrawal on downstream targets in androgen-dependent LNCaP cells.
|
10939590 |
2000 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
PSM, a new prostate antigen is valuable as a marker for hematogenous micro-metastatic tumor dissemination as detected in RT-PCR assays of peripheral blood.
|
9215402 |
1997 |